Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director · President and CEO | February 12, 2024 | February 14, 2024 |
| Indivior Pharmaceuticals, Inc.INDV · Entity 4040 | Director · Chief Executive Officer | June 22, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date February 12, 2024 · Filed February 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 444,867 |
Ending reported balance
After 2024-02-12 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-02-12 · Grant · Acquired 119,000 · Balance 394,000 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Row 2 · 2024-02-12 · Grant · Acquired 179,734 · Balance 573,734 F2: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 179,734 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Row 3 · 2024-02-12 · Tax withholding · Disposed 47,445 · Balance 526,289 F3: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Row 4 · 2024-02-12 · Tax withholding · Disposed 81,422 · Balance 444,867 F4: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
F2: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 179,734 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.
F3: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.
F4: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.
Indivior Pharmaceuticals, Inc.
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 790,330 |
Ending reported balance
After 2026-06-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-22 · Exercise / conversion · Acquired 1,266,903 · Balance 1,402,879 F1: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026. F2: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-06-22 · Tax withholding · Disposed 612,549 · Balance 790,330 F3: Shares withheld to satisfy tax withholding obligations associated with the vesting of performance stock units on June 22, 2026. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-22 · Exercise / conversion · Disposed 1,266,903 · Balance 0 F2: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. F1: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of performance stock units upon the determination that the performance conditions were met at 100% with respect to the performance stock units granted to the Reporting Person on May 13, 2025. As a result, 1,266,903 shares vested on June 22, 2026.
F2: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: Shares withheld to satisfy tax withholding obligations associated with the vesting of performance stock units on June 22, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2022 Filed Nov 22, 2022 21:44 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,989 | $22.02 | $43,797.78 |
DisclosureSEC source: 0001062993-22-022644 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,453 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.00 to $22.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 21:44 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 1,989 | $15.90 | $31,625.10 |
DisclosureSEC source: 0001062993-22-022644 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:35 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,394 | $18.16 | $25,315.04 |
DisclosureSEC source: 0001062993-22-016068 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,453 F1 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 11,011 | $19.04 | $209,649.44 |
DisclosureSEC source: 0001062993-22-006644 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,847 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2021. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.91 to $19.35, inclusive. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 65,083 | $18.37 | $1,195,574.71 |
DisclosureSEC source: 0001062993-22-006644 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,858 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2021. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.90 to $18.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 23:37 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 28,843 | $17.63 | $508,502.09 |
DisclosureSEC source: 0001062993-22-004320 · form4.xml · nonDerivative · entry 4 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,941 F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 23:37 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 24,154 | $17.63 | $425,835.02 |
DisclosureSEC source: 0001062993-22-004320 · form4.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,784 F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 23:37 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 65,034 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-004320 · form4.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,938 F2 · price: On February 10, 2022, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 65,034 performance share units granted in the issuer's three prior fiscal years. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 23:37 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004320 · form4.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,904 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2023, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,090 | $18.68 | $20,361.20 |
DisclosureSEC source: 0001879789-22-000001 · primary_doc.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,904 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 20:01 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,386 | $19.03 | $26,375.58 |
DisclosureSEC source: 0001192482-21-000661 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,994 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:03 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,394 | $23.99 | $33,442.06 |
DisclosureSEC source: 0001192482-21-000623 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,380 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 20:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 5,861 | $22.81 | $133,689.41 |
DisclosureSEC source: 0001192482-21-000479 · edgar.xml · nonDerivative · entry 5 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,774 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2020. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 16,205 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001192482-21-000479 · edgar.xml · derivative · entry 6 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,205 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All of the 16,205 option shares are exercisable. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 10,829 | $23.33 | $252,640.57 |
DisclosureSEC source: 0001192482-21-000479 · edgar.xml · nonDerivative · entry 4 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,635 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2020. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.88, inclusive. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 5,376 | $22.93 | $123,271.68 |
DisclosureSEC source: 0001192482-21-000479 · edgar.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,464 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2020. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.79 to $22.99, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (3) and (4). Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 16,205 | $8.22 | $133,205.10 |
DisclosureSEC source: 0001192482-21-000479 · edgar.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 4,672 | $22.90 | $106,988.80 |
DisclosureSEC source: 0001192482-21-000479 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,635 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:02 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 48,616 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001192482-21-000212 · edgar.xml · derivative · entry 4 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,205 Underlying: Common Stock · 48,616 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 48,616 shares under the option are exercisable. The option, initially representing a right to purchase a total of 259,283 shares, vests and becomes exercisable over a four-year period commencing on May 31, 2017. Twenty-five percent (25%) of the option vested and became exercisable on May 31, 2018 and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) at the end of each quarterly period over the remaining three years of the four-year period, subject to the reporting person's continued service with the Issuer. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:02 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 9,809 | $23.30 | $228,549.70 |
DisclosureSEC source: 0001192482-21-000212 · edgar.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,307 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2020. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.54, inclusive. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:02 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 54,959 | $22.56 | $1,239,875.04 |
DisclosureSEC source: 0001192482-21-000212 · edgar.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,116 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.01 to $22.98, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3). Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:02 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 48,616 | $8.22 | $399,623.52 |
DisclosureSEC source: 0001192482-21-000212 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 15,288 | $25.95 | $396,723.60 |
DisclosureSEC source: 0001192482-21-000148 · edgar.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,459 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 8,498 | $25.95 | $220,523.10 |
DisclosureSEC source: 0001192482-21-000148 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,747 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 420,000 | $0.00 Strike: $24.06 | $0.00 |
DisclosureSEC source: 0001192482-21-000083 · edgar.xml · derivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,000 Underlying: Common Stock · 420,000 shares Expires 2031-01-19 F3 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2022, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 28,989 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-21-000083 · edgar.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,245 F2 · price: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 28,989 performance share units granted in two prior years. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000083 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,256 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 21:13 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 28,989 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-21-000103 · edgar.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,245 F2 · price: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 28,989 performance share units granted in two prior years. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 21:13 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000103 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,256 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:09 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,090 | $20.03 | $21,832.70 |
DisclosureSEC source: 0001192482-21-000045 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,256 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:00 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 4,672 | $18.49 | $86,385.28 |
DisclosureSEC source: 0001192482-20-000797 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,346 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,386 | $18.89 | $26,181.54 |
DisclosureSEC source: 0001192482-20-000667 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,018 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:40 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,394 | $17.37 | $24,213.78 |
DisclosureSEC source: 0001192482-20-000600 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,404 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| June 02, 2020 Filed Jun 2, 2020 22:58 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 100 | $21.30 | $2,130.00 |
DisclosureSEC source: 0001192482-20-000418 · edgar.xml · nonDerivative · entry 6 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,798 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019. Read SEC document |
| June 02, 2020 Filed Jun 2, 2020 22:58 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 5,761 | $20.47 | $117,927.67 |
DisclosureSEC source: 0001192482-20-000418 · edgar.xml · nonDerivative · entry 5 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,898 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.18 to $20.92, inclusive. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 22:58 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 64,820 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001192482-20-000418 · edgar.xml · derivative · entry 7 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,821 Underlying: Common Stock · 64,820 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 64,820 shares under the option are exercisable. The option, initially representing a right to purchase a total of 259,283 shares, vests and becomes exercisable over a four-year period commencing on May 31, 2017. Twenty-five percent (25%) of the option vested and became exercisable on May 31, 2018 and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) at the end of each quarterly period over the remaining three years of the four-year period, subject to the reporting person's continued service with the Issuer. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 22:58 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 100 | $22.08 | $2,208.00 |
DisclosureSEC source: 0001192482-20-000418 · edgar.xml · nonDerivative · entry 4 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,659 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 22:58 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 70,576 | $21.53 | $1,519,501.28 |
DisclosureSEC source: 0001192482-20-000418 · edgar.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,759 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.05 to $22.02, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (3) and (4). Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 22:58 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 64,820 | $8.22 | $532,820.40 |
DisclosureSEC source: 0001192482-20-000418 · edgar.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 22:58 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 4,672 | $21.24 | $99,233.28 |
DisclosureSEC source: 0001192482-20-000418 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,515 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 7,499 | $21.62 | $162,128.38 |
DisclosureSEC source: 0001192482-20-000152 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,187 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 90,000 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001192482-20-000135 · edgar.xml · derivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2030-02-05 F2 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000135 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,686 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2021, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:07 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,091 | $20.58 | $22,452.78 |
DisclosureSEC source: 0001192482-20-000002 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,686 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| November 29, 2019 Filed Dec 2, 2019 21:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 4,678 | $21.73 | $101,652.94 |
DisclosureSEC source: 0001192482-19-000451 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,777 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 21:11 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 64,821 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001192482-19-000392 · edgar.xml · derivative · entry 4 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,641 Underlying: Common Stock · 64,821 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 81,026 shares under the option are exercisable. The option, initially representing a right to purchase a total of 259,283 shares, vests and becomes exercisable over a four-year period commencing on May 31, 2017. Twenty-five percent (25%) of the option vested and became exercisable on May 31, 2018 and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) at the end of each quarterly period over the remaining three years of the four-year period, subject to the reporting person's continued service with the Issuer. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 21:11 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 31,226 | $19.16 | $598,290.16 |
DisclosureSEC source: 0001192482-19-000392 · edgar.xml · nonDerivative · entry 3 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,455 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2018. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 21:11 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 33,595 | $18.41 | $618,483.95 |
DisclosureSEC source: 0001192482-19-000392 · edgar.xml · nonDerivative · entry 2 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,681 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2018. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.13 to $18.53, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 21:11 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 64,821 | $8.22 | $532,828.62 |
DisclosureSEC source: 0001192482-19-000392 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 20:46 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 919 | $11.24 | $10,329.56 |
DisclosureSEC source: 0001192482-19-000339 · edgar.xml · nonDerivative · entry 1 Ciaffoni Joseph · CIK 0001443841 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,455 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.